9,113 Shares in Exelixis, Inc. (NASDAQ:EXEL) Acquired by Coldstream Capital Management Inc.

Coldstream Capital Management Inc. acquired a new stake in Exelixis, Inc. (NASDAQ:EXEL) during the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 9,113 shares of the biotechnology company’s stock, valued at approximately $238,000.

A number of other large investors also recently modified their holdings of EXEL. SG Americas Securities LLC purchased a new position in Exelixis in the second quarter valued at $489,000. Blue Trust Inc. increased its holdings in shares of Exelixis by 81.4% in the 2nd quarter. Blue Trust Inc. now owns 3,953 shares of the biotechnology company’s stock valued at $94,000 after acquiring an additional 1,774 shares during the last quarter. Raymond James & Associates increased its holdings in shares of Exelixis by 1.2% in the 2nd quarter. Raymond James & Associates now owns 109,856 shares of the biotechnology company’s stock valued at $2,468,000 after acquiring an additional 1,328 shares during the last quarter. Fifth Third Wealth Advisors LLC acquired a new stake in shares of Exelixis during the 2nd quarter worth about $216,000. Finally, Retirement Systems of Alabama lifted its stake in Exelixis by 92.1% during the second quarter. Retirement Systems of Alabama now owns 731,476 shares of the biotechnology company’s stock worth $16,436,000 after purchasing an additional 350,740 shares during the last quarter. 85.27% of the stock is owned by hedge funds and other institutional investors.

Exelixis Price Performance

Exelixis stock opened at $36.07 on Tuesday. The business has a 50 day simple moving average of $32.85 and a 200-day simple moving average of $27.29. Exelixis, Inc. has a 12 month low of $19.20 and a 12 month high of $36.97. The stock has a market capitalization of $10.30 billion, a PE ratio of 23.12, a price-to-earnings-growth ratio of 0.89 and a beta of 0.52.

Exelixis (NASDAQ:EXEL) last announced its quarterly earnings data on Tuesday, October 29th. The biotechnology company reported $0.40 EPS for the quarter, topping analysts’ consensus estimates of $0.36 by $0.04. The company had revenue of $539.50 million during the quarter, compared to the consensus estimate of $490.31 million. Exelixis had a net margin of 22.43% and a return on equity of 20.99%. Exelixis’s quarterly revenue was up 14.3% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.10 EPS. As a group, equities research analysts anticipate that Exelixis, Inc. will post 1.69 EPS for the current year.

Insider Buying and Selling

In related news, EVP Dana Aftab sold 1,162 shares of the company’s stock in a transaction on Wednesday, October 30th. The stock was sold at an average price of $31.40, for a total transaction of $36,486.80. Following the transaction, the executive vice president now owns 498,945 shares of the company’s stock, valued at $15,666,873. This represents a 0.23 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Jeffrey Hessekiel sold 60,000 shares of the business’s stock in a transaction on Friday, November 29th. The stock was sold at an average price of $36.67, for a total transaction of $2,200,200.00. Following the sale, the executive vice president now owns 486,059 shares in the company, valued at $17,823,783.53. The trade was a 10.99 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 339,736 shares of company stock valued at $11,508,610 over the last ninety days. Corporate insiders own 2.85% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have commented on EXEL. Stephens increased their price target on shares of Exelixis from $23.00 to $29.00 and gave the company an “equal weight” rating in a research note on Wednesday, October 30th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $34.00 target price on shares of Exelixis in a research report on Wednesday, October 30th. HC Wainwright reissued a “buy” rating and issued a $29.00 price target on shares of Exelixis in a research report on Wednesday, September 18th. Truist Financial raised their price objective on Exelixis from $33.00 to $38.00 and gave the stock a “buy” rating in a report on Wednesday, October 30th. Finally, Wells Fargo & Company boosted their target price on Exelixis from $32.00 to $36.00 and gave the company an “overweight” rating in a report on Wednesday, October 30th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $31.47.

Exelixis Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.